Related Experiment Videos

Meningeal penetration of apalcillin in man

Insights

Apalcillin shows poor meningeal penetration in non-meningitis patients but achieves therapeutic levels in meningitis cases. A dosage of 200 mg/kg/day may treat meningitis caused by susceptible bacteria, including Pseudomonas aeruginosa.

Area of Science:

  • Pharmacokinetics
  • Infectious Diseases
  • Neuroscience

Background:

  • Apalcillin is an antibiotic.
  • Meningeal penetration of antibiotics is crucial for treating meningitis.
  • Previous data on apalcillin's CSF penetration is limited.

Purpose of the Study:

  • To evaluate the meningeal penetration of apalcillin in patients with and without meningitis.
  • To determine if apalcillin levels in cerebrospinal fluid (CSF) are sufficient for treating bacterial meningitis.

Main Methods:

  • High-performance liquid chromatography (HPLC) was used to measure apalcillin concentrations.
  • Apalcillin levels were assessed in serum and CSF of patients.
  • Patient groups included those without meningitis and those with confirmed meningitis.

Main Results:

  • In subjects without meningitis, apalcillin penetration was poor, with levels not exceeding 1.75 mg/l.
  • In meningitis patients with CSF albumin > 0.60 g/l, apalcillin levels ranged from 5 to 30 mg/l.
  • These results align with findings from experimental meningitis models.

Conclusions:

  • Apalcillin demonstrates significant meningeal penetration in the presence of meningitis, particularly when CSF albumin is elevated.
  • A dosage of 200 mg/kg/day is proposed as potentially effective for treating meningitis caused by susceptible bacteria, including Pseudomonas aeruginosa.

Related Concept Videos